190 related articles for article (PubMed ID: 26589819)
21. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
[TBL] [Abstract][Full Text] [Related]
22. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
[TBL] [Abstract][Full Text] [Related]
23. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
[TBL] [Abstract][Full Text] [Related]
25. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
[TBL] [Abstract][Full Text] [Related]
26. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
Barzilay JI; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Black HR; Cushman WC; Ford CE; Margolis KL; Moloo J; Oparil S; Piller LB; Simmons DL; Sweeney ME; Whelton PK; Wong ND; Wright JT;
Circ Cardiovasc Qual Outcomes; 2012 Mar; 5(2):153-62. PubMed ID: 22396585
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR;
Hypertension; 2012 May; 59(5):926-33. PubMed ID: 22431578
[TBL] [Abstract][Full Text] [Related]
29. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
[TBL] [Abstract][Full Text] [Related]
30. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
31. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Haywood LJ; Davis BR; Piller LB; Simpson LM; Ghosh A; Einhorn PT; Ford CE; Probstfield JL; Soliman EZ; Wright JT;
J Natl Med Assoc; 2018 Aug; 110(4):343-351. PubMed ID: 30126559
[TBL] [Abstract][Full Text] [Related]
32. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
33. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
Puttnam R; Davis BR; Pressel SL; Whelton PK; Cushman WC; Louis GT; Margolis KL; Oparil S; Williamson J; Ghosh A; Einhorn PT; Barzilay JI;
JAMA Intern Med; 2017 Jan; 177(1):67-76. PubMed ID: 27893045
[TBL] [Abstract][Full Text] [Related]
34. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Lynch AI; Eckfeldt JH; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2012 May; 22(5):355-66. PubMed ID: 22388798
[TBL] [Abstract][Full Text] [Related]
35. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
[TBL] [Abstract][Full Text] [Related]
36. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Zhang X; Lynch AI; Davis BR; Ford CE; Boerwinkle E; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
PLoS One; 2012; 7(3):e34217. PubMed ID: 22470539
[TBL] [Abstract][Full Text] [Related]
38. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
